Penn Mutual Life Insurance Co Trims Holdings in Aimmune Therapeutics, Inc. (AIMT)

Penn Mutual Life Insurance Co trimmed its stake in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 51.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,000 shares of the biotechnology company’s stock after selling 20,000 shares during the quarter. Aimmune Therapeutics comprises about 0.3% of Penn Mutual Life Insurance Co’s holdings, making the stock its 22nd biggest position. Penn Mutual Life Insurance Co’s holdings in Aimmune Therapeutics were worth $401,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of AIMT. SG Americas Securities LLC grew its holdings in Aimmune Therapeutics by 10.1% in the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 499 shares during the period. Legal & General Group Plc grew its holdings in shares of Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Aimmune Therapeutics by 31.2% during the second quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 3,757 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in shares of Aimmune Therapeutics during the second quarter valued at about $333,000. Finally, Citadel Advisors LLC acquired a new position in shares of Aimmune Therapeutics during the second quarter valued at about $360,000. Institutional investors and hedge funds own 73.34% of the company’s stock.

Aimmune Therapeutics, Inc. (AIMT) opened at $35.36 on Thursday. Aimmune Therapeutics, Inc. has a 12-month low of $15.97 and a 12-month high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.09. sell-side analysts forecast that Aimmune Therapeutics, Inc. will post -2.57 earnings per share for the current year.

In related news, CEO Stephen George Dilly sold 100,000 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $25.01, for a total transaction of $2,501,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Douglas T. Sheehy sold 1,906 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $38.66, for a total transaction of $73,685.96. Following the transaction, the insider now directly owns 1,906 shares in the company, valued at $73,685.96. The disclosure for this sale can be found here. Insiders have sold 274,986 shares of company stock worth $7,533,100 over the last three months. 17.59% of the stock is owned by insiders.

A number of brokerages have recently issued reports on AIMT. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Saturday, October 21st. BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Credit Suisse Group lifted their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a report on Monday, October 23rd. Zacks Investment Research cut shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, ValuEngine cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $53.80.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thestockobserver.com/2017/12/07/penn-mutual-life-insurance-co-trims-holdings-in-aimmune-therapeutics-inc-aimt.html.

Aimmune Therapeutics Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics, Inc. (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply